Amanda Leigh Elchynski

Dr. Amanda Leigh Elchynski

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RGRoseann S. Gammal
Roseann S. Gammal
MPMunir Pirmohamed
Munir Pirmohamed
ASAndrew A. Somogyi
Andrew A. Somogyi
SMSarah A. Morris
Sarah A. Morris
CFChristine M. Formea
Christine M. Formea
MRMary V. Relling
Mary V. Relling
Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia in the setting of oxidative stress, which can be caused by medication exposure. Regulatory agencies worldwide warn against the use of certain medications in persons with G6PD deficiency, but in many cases, this information is conflicting, and the clinical evidence is sparse. This guideline provides information on using G6PD genotype as part of the diagnosis of G6PD deficiency and classifies medications that have been previously implicated as unsafe in individuals with G6PD deficiency by one or more sources. We classify these medications as high, medium, or low to no risk based on a systematic review of the published evidence of the gene–drug associations and regulatory warnings. In patients with G6PD deficiency, high‐risk medications should be avoided, medium‐risk medications should be used with caution, and low‐to‐no risk medications can be used with standard precautions, without regard to G6PD phenotype. This new document replaces the prior Clinical Pharmacogenetics Implementation Consortium guideline for rasburicase therapy in the context of G6PD genotype (updates at: www.cpicpgx.org).

25 September 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
STSony Tuteja
Sony Tuteja
RSRamzi Salloum
Ramzi Salloum
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
DSD. Max Smith
D. Max Smith
ERElizabeth Rowe
Elizabeth Rowe
FGfor the IGNITE Pharmacogenetics Working Group
for the IGNITE Pharmacogenetics Working Group
There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented or were in the process of implementing PGx testing for antidepressants. Survey 1 collected data on the process and logistics of testing. Survey 2 asked sites to rank the importance of Consolidated Framework for Implementation Research (CFIR) constructs using best‐worst scaling choice experiments. Of the 17 sites, 13 had implemented testing and four were in the planning stage. Thirteen offered testing in the outpatient setting, and nine in both outpatient/inpatient settings. PGx tests were mainly ordered by psychiatry (92%) and primary care (69%) providers. CYP2C19 and CYP2D6 were the most commonly tested genes. The justification for antidepressants selected for PGx guidance was based on Clinical Pharmacogenetics Implementation Consortium guidelines (94%) and US Food and Drug Administration (FDA; 75.6%) guidance. Both institutional (53%) and commercial laboratories (53%) were used for testing. Sites varied on the methods for returning results to providers and patients. Sites were consistent in ranking CFIR constructs and identified patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and the identification of champions as most important for implementation. Sites deployed similar implementation strategies and measured similar outcomes. The process of implementing PGx testing to guide antidepressant therapy varied across sites, but key drivers for successful implementation were similar and may help guide other institutions interested in providing PGx‐guided pharmacotherapy for antidepressant management.

18 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
NDNina Desai
Nina Desai
DDDanielle D’Silva
Danielle D’Silva
BHBradley Hall
Bradley Hall
YMYael Marks
Yael Marks
KNKhoa A Nguyen
Khoa A Nguyen
A formal assessment of pharmacogenomics clinical decision support (PGx-CDS) by providers is lacking in the literature. The objective of this study was to evaluate the usability of PGx-CDS tools that have been implemented in a healthcare setting. We enrolled ten prescribing healthcare providers and had them complete a 60-min usability session, which included interacting with two PGx-CDS scenarios using the “Think Aloud” technique, as well as completing the Computer System Usability Questionnaire (CSUQ). Providers reported positive comments, negative comments, and suggestions for the two PGx-CDS during the usability testing. Most provider comments were in favor of the current PGx-CDS design, with the exception of how the genotype and phenotype information is displayed. The mean CSUQ score for the PGx-CDS overall satisfaction was 6.3 ± 0.95, with seven strongly agreeing and one strongly disagreeing for overall satisfaction. The implemented PGx-CDS at our institution was well received by prescribing healthcare providers. The feedback collected from the session will guide future PGx-CDS designs for our healthcare system and provide a framework for other institutions implementing PGx-CDS.

19 September 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MEMichael Eadon
Michael Eadon
David W. HeinDavid W. Hein
David W. Hein
MAMichael A. Andersen
Michael A. Andersen
ACArlene B. Chapman
Arlene B. Chapman
RCRhonda M Cooper-Dehoff
Rhonda M Cooper-Dehoff
Jose AgundezJose Agundez
Jose Agundez
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with NAT2 rapid and intermediate metabolizers (historically referred to as “rapid acetylators” and “intermediate acetylators,” respectively), which may lead to both increased clinical efficacy and adverse effects, including drug‐induced systemic lupus erythematosus. This guideline summarizes the evidence from the literature relevant to NAT2 /hydralazine and provides recommendations for hydralazine prescribing based on NAT2 genotype‐predicted acetylator phenotype (updates at www.cpicpgx.org ).

Verified
Journal Article
Open access
PDF file
Pritmohinder S GillPritmohinder S Gill
Pritmohinder S Gill
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
PPPatricia Porter-Gill
Patricia Porter-Gill
BGBradley G. Goodson
Bradley G. Goodson
MSMary Ann Scott
Mary Ann Scott
GSGerald Schaefer
Gerald Schaefer
Neurodevelopmental disorders have steadily increased in incidence in the United States. Over the past decade, there have been significant changes in clinical diagnoses and treatments some of which are due to the increasing adoption of pharmacogenomics (PGx) by clinicians. In this pilot study, a multidisciplinary team at the Arkansas Children’s Hospital North West consulted on 27 patients referred for difficult-to-manage neurodevelopmental and/or neurobehavioral disorders. The 27 patients were evaluated by the team using records review, team discussion, and pharmacogenetic testing. OneOme RightMed® (Minneapolis, MN, USA) and the Arkansas Children’s Hospital comprehensive PGx test were used for drug prescribing guidance. Of the 27 patients’ predicted phenotypes, the normal metabolizer was 11 (40.8%) for CYP2C19 and 16 (59.3%) for CYP2D6. For the neurodevelopmental disorders, the most common comorbid conditions included attention-deficit hyperactivity disorder (66.7%), anxiety disorder (59.3%), and autism (40.7%). Following the team assessment and PGx testing, 66.7% of the patients had actionable medication recommendations. This included continuing current therapy, suggesting an appropriate alternative medication, starting a new therapy, or adding adjunct therapy (based on their current medication use). Moreover, 25.9% of patients phenoconverted to a CYP2D6 poor metabolizer. This retrospective chart review pilot study highlights the value of a multidisciplinary treatment approach to deliver precision healthcare by improving physician clinical decisions and potentially impacting patient outcomes. It also shows the feasibility to implement PGx testing in neurodevelopmental/neurobehavioral disorders.

24 July 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
ECEmily J Cicali
Emily J Cicali
EEElizabeth Eddy
Elizabeth Eddy
YGYan Gong
Yan Gong
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
KAKim Pena del Aguila
Kim Pena del Aguila
RCRhonda M Cooper-Dehoff
Rhonda M Cooper-Dehoff
The University of Florida Health conducted a pragmatic implementation of a pharmacogenetics (PGx) panel‐based test to guide medications used for supportive care prescribed to patients undergoing chemotherapy. The implementation was in the context of a pragmatic clinical trial for patients with non‐hematologic cancers being treated with chemotherapy. Patients were randomized to either the intervention arm or control arm and received PGx testing immediately or at the end of the study, respectively. Patients completed the MD Anderson Symptom Inventory (MDASI) to assess quality of life (QoL). A total of 150 patients received PGx testing and enrolled in the study. Clinical decision support and implementation infrastructure were developed. While the study was originally planned for 500 patients, we were underpowered in our sample of 150 patients to test differences in the patient‐reported MDASI scores. We did observed a high completion rate (92%) of the questionnaires; however, there were few medication changes (n = 6 in the intervention arm) based on PGx test results. Despite this, we learned several lessons through this pragmatic implementation of a PGx panel‐based test in an outpatient oncology setting. Most notably, patients were less willing to undergo PGx testing if the cost of the test exceeded $100. In addition, to enhance PGx implementation success, reoccurring provider education is necessary, clinical decision support needs to appear in a more conducive way to fit in with oncologists' workflow, and PGx test results need to be available earlier in treatment planning.